Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability

Trends in Pharmacological Sciences

Volumn 18, Issue 1, 1997, Pages 21-25

  Curzon, Gerald ^a   Gibson, E Leigh ^b   Oluyomi, Ademola O ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 1 (1 NAPHTHYL)PIPERAZINE; ANOREXIGENIC AGENT; DEXFENFLURAMINE; DRUG METABOLITE; FENCLONINE; FLUOXETINE; METERGOLINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NEUROPEPTIDE Y; NORFENFLURAMINE; SEROTONIN; SEROTONIN 1C RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

APPETITE; BODY WEIGHT; DRUG MECHANISM; FEEDING; FEMALE; FOOD INTAKE; HUMAN; HYPERPHAGIA; HYPOPHAGIA; MALE; NONHUMAN; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

EID: 0031015701     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(96)01003-6     Document Type: Note

References (51)

1. 1 Garrow, J. (1991) Br. Med. J. 303, 704-706
2. 2 Snow, J. T. and Harris, M. B. (1986) J. Obes. Weight Regul. 5, 195-214
3. 3 Wiseman, C. V., Gray, J. J., Mosimann, J. E. and Ahrens, A. H. (1992) Int. J. Eating Disord. 11, 85-89
4. 4 Kuczmarski, R. J., Flegal, K. M., Campbell, S. M. and Johnson, C. L. (1994) J. Am. Med. Soc. 272, 205-211
5. 5 Bennett, N. et al. (1995) Health Survey for England 1993, HMSO
6. 6 Garner, D. M. and Wooley, S. C. (1991) Clin. Psychol. Rev. 11, 729-780
7. 7 Guy-Grand, B. (1995) Obes. Res. 3 (Suppl. 4), 491S-496S
8. 8 Kogon, M. M. et al. (1994) Am. J. Clin. Nutr. 60, 488-493
9. 9 Blundell, J. E. (1977) Int. J. Obes. 1, 15-42
10. 10 Curzon, G. (1992) in Serotonin Receptor Subtypes: Pharmacological Significance and Clinical Implications (Langer, S. Z. et al., eds), pp. 112-128, Karger
11. 11 Oluyomi, A. O., Gibson, E. L., Barnfield, A. M. C. and Curzon, G. (1994) Eur. J. Pharmacol. 264, 111-115
12. 12 Leibowitz, S. F., Weiss, G. F. and Shor-Posner, G. (1988) Clin. Neuropharmacol. 11 (Suppl. 1), S51-S71
13. 13 Fletcher, P. J., Currie, P. J., Chambers, J. W. and Coscina, D. V. (1993) Brain Res. 630, 1-9
14. 14 Gibson, E. L., Kennedy, A. J. and Curzon, G. (1993) Eur J. Pharmacol. 242, 83-90
15. 15 Borsini, F., Bendotti, C., Aleotti, A., Samanin, R. and Garattini, S. (1982) Pharmacol. Res. Commun. 14, 671-678
16. 16 Raiteri, M., Bonanno, G. and Vallebuona, F. (1995) J. Pharmacol. Exp. Ther. 273, 643-649
17. 17 McCann, U. D., Yuan, J. and Ricaurte, G. A. (1995) Eur. J. Pharmacol. 283, R5-R7
18. 18 Callaway, C. W., Wing, L. L., Nichols, D. E. and Geyer, M. A. (1993) Psychopharmacology 111, 169-178
19. 19 Silverstone, T. (1992) Drugs 43, 820-836
20. 20 Grignaschi, G. and Samanin, R. (1992) Neuropharmacology 31, 445-449
21. 21 Lightowler, S. et al. (1996) Eur. J. Pharmacol. 296, 137-143
22. 22 Caccia, S. et al. (1992) J. Pharm. Pharmacol. 44, 250-254
23. 23 Kennedy, A. J., Gibson, E. L., O'Connell, M. T. and Curzon, G. (1993) Psychopharmacology 113, 262-268
24. 24 Caccia, S. et al. (1993) Eur. J. Pharmacol. 233, 71-77
25. 25 Mennini, T. et al. (1991) Naunyn-Schmiedeberg's Arch. Pharmacol. 343, 483-490
26. 26 Kennett, G. A. and Curzon, G. (1991) Br. J. Pharmacol. 103, 2016-2020
27. 27 Lucki, I., Kreider, M. S. and Simansky, K. J. (1988) Psychopharmacology 96, 289-295
28. 28 Cervo, L., Grignaschi, G., Rossi, C. and Samanin, R. (1991) Eur. J. Pharmacol. 196, 217-222
29. 29 Grignaschi, G. and Samanin, R. (1993) Psychopharmacology 110, 203-208
30. 30 Tohyama, I., Kameyama, I. and Kimura, H. (1988) Neuroscience 26, 971-991
31. 31 Koe, B. K. and Weissman, A. (1968) Adv. Pharmacol. 6B, 29-47
32. 32 Stephens, R. L., Garrick, T., Weiner, H. and Tache, Y. (1989) J. Pharmacol. Exp. Ther. 251, 524-530
33. 33 Baker, B. J., Duggan, J. P., Barber, D. J. and Booth, D. A. (1988) Eur. J. Pharmacol. 150, 137-142
34. 34 Samanin, R. et al. (1991) Eur. J. Pharmacol. 197, 69-73
35. 35 Neill, J. C. and Cooper, S. J. (1989) Psychopharmacology 97, 213-218
36. 36 Caccia, S. et al. (1992) Xenobiotica 22, 217-226
37. 37 Tecott, L. H. et al. (1995) Nature 374, 542-546
38. 38 Hartley, J. E., Brown, G. and Dourish, C. T. (1995) Br. J. Pharmacol. 114, 373P
39. 39 Lovenberg, T. W. et al. (1993) Neuron 11, 449-458
40. 40 Shen, Y. et al. (1993) J. Biol. Chem. 268, 18200-18204
41. 41 Wong, D. T., Threlkeld, P. G. and Robertson, D. W. (1991) Neuropsychopharmacology 5, 43-47
42. 42 De Deurwaerdere, P., Bonhomne, N., Le Moal, M. and Spampinato, V. (1995) J. Neurochem. 65, 1100-1108
43. 43 Ahlskog, J. E., Randall, P. K., Hernandez, L. and Hoebel, B. G. (1984) Psychopharmacology 82, 118-121
44. 44 Leibowitz, S. F. (1991) Brain Res. Bull. 27, 333-337
45. 45 Brown, C. M. and Coscina, D. V. (1995) Pharmacol. Biochem. Behav. 51, 641-646
46. 46 Grignaschi, G., Sironi, F. and Samanin, R. (1995) Eur. J. Pharmacol. 274, 221-224
47. 47 Dryden, S., Frankish, H. M., Kilpatrick, A. and Williams, G. (1994) Clin. Sci. 86, 43P
48. 48 Dryden, S. et al. (1996) Neuroscience 72, 557-566
49. 49 Souquet, A-M. and Rowland, N. E. (1990) Am. J. Physiol. 258, R211-R215
50. 50 Oluyomi, A. O., Datla, K. P. and Curzon, G. (1994) Eur. J. Pharmacol. 255, 175-183
51. 51 Blanchard, D. C., Griebel, G. and Blanchard, R. J. (1995) J. Psychopharmacol. 9, 79-82